Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3, randomized, open-label, multicenter study to evaluate the efficacy and safety of AP301 on serum phosphorus control in chronic kidney disease patients receiving maintenance dialysis with hyperphosphatemia in China

Next Previous
X
Search
Trial Profile

A phase 3, randomized, open-label, multicenter study to evaluate the efficacy and safety of AP301 on serum phosphorus control in chronic kidney disease patients receiving maintenance dialysis with hyperphosphatemia in China

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 13 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VS-505 (Primary)
  • Indications Hyperphosphataemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Shanghai Alebund Pharmaceuticals

    • Most Recent Events

    • 13 Jan 2025 New trial record
    • 07 Jan 2025 According to an Alebund Pharmaceuticals media release, company announced the closing of RMB 550 million in Series C financing, this round of financing will support accelerating new drug application (NDA) in China for the best-in-class iron-based phosphate binder AP301.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top